Last reviewed: March 2026
Contents
MDM Templates
Viral Illness / Non-Endemic Region
Patient with recent travel to *** presents with fever, myalgias, and malaise. They are fully vaccinated without history of immunosuppression. They deny mucosal lesions, palm or sole rash, severe arthralgias, or hemorrhagic features. They are well appearing and hemodynamically stable.
Travel region is not endemic for malaria, making thick smear unnecessary at this time. History and exam lower suspicion for malaria, dengue, typhoid, measles, new HIV seroconversion, Ebola, or other travel-specific pathology. Presentation is most consistent with self-limiting viral exanthem.
Plan: Supportive care with antipyretics and hydration.
Disposition: Discharge with return precautions for persistent high fevers, new rash, jaundice, altered mental status, or inability to tolerate PO. PCP follow-up within 48 hours.
Malaria-Endemic Region
Patient with recent travel to a malaria-endemic region presents with fever, rigors, and malaise. Travel-specific infections including malaria must be actively excluded given exposure history.
History and exam do not reliably exclude malaria even in a well-appearing patient. Presentation also requires consideration of dengue, typhoid, chikungunya, and other region-specific infections.
Plan: Thick and thin smears, CBC, BMP, LFTs. Case reported to State Health Department.
If smears negative, clinically stable:
Disposition: Discharge with mandatory repeat smears at 12 and 24 hours (single negative smear does not exclude malaria). Return precautions for worsening fever, confusion, jaundice, or dark urine.
If smears positive, uncomplicated (parasitemia <5%, tolerating PO, no end-organ dysfunction):
Plan: Atovaquone-proguanil (Malarone) 1000mg/400mg PO daily x 3 days OR artemether-lumefantrine (Coartem) per dosing schedule.
Disposition: Discharge if tolerating PO and not immunosuppressed. Close follow-up within 24 hours.
If smears positive, severe (parasitemia >5%, AMS, renal failure, ARDS, severe anemia, hemodynamic instability):
Plan: IV artesunate (contact CDC for distribution: 770-488-7788, after hours: 770-448-7100).
Disposition: ICU admission.
Clinical Education
Travel Differential by Region
| Region | Key Considerations |
| Sub-Saharan Africa | Malaria (P. falciparum dominant), typhoid, Ebola (outbreak-dependent) |
| South/Southeast Asia | Dengue, malaria (P. vivax more common), typhoid, chikungunya, Japanese encephalitis |
| Central/South America | Dengue, Zika, chikungunya, malaria (select regions), Chagas |
| Caribbean | Dengue, chikungunya, Zika, malaria (Haiti/Dominican Republic) |
| Middle East | MERS (coronavirus), brucellosis, leishmaniasis |
Malaria Pearls
Malaria can present weeks to months after travel. Incubation for P. falciparum is typically 7-30 days but P. vivax/ovale can relapse months later from dormant liver hypnozoites. Always ask about travel history in any unexplained fever.[1]
Thrombocytopenia is the most sensitive lab finding — present in >80% of malaria cases. Anemia and elevated bilirubin from hemolysis are also common. A febrile traveler with low platelets and anemia should have malaria at the top of the differential.[1]
Thick smear detects parasites; thin smear identifies species. A single negative smear does not rule out malaria — parasitemia can be intermittent. Repeat at 12- and 24-hour intervals. Rapid diagnostic tests (RDTs) are available at some institutions as an adjunct.[2]
Malaria Treatment
| Severity | Treatment | Notes |
| Uncomplicated | Atovaquone-proguanil (Malarone) OR artemether-lumefantrine (Coartem) | Outpatient if tolerating PO, not immunosuppressed, parasitemia <5%, no end-organ dysfunction |
| Severe | IV artesunate | CDC Malaria Hotline: 770-488-7788. After hours: 770-448-7100. Quinidine no longer available (discontinued 2019). |
Severe malaria criteria: Parasitemia >5% (some use >2% in non-immune travelers), AMS/cerebral malaria, ARDS, severe anemia (Hgb <7), renal failure, DIC, hemodynamic instability, hypoglycemia.[3]
Dengue Recognition
Classic presentation: High fever + severe arthralgias/myalgias (“breakbone fever”) + retro-orbital headache + rash (typically appearing days 3-5). Labs show leukopenia, thrombocytopenia, and mildly elevated transaminases.[4]
Warning signs for severe dengue: Abdominal pain, persistent vomiting, clinical fluid accumulation (ascites, pleural effusion), mucosal bleeding, lethargy, hepatomegaly, rising hematocrit with falling platelets. These patients need admission for close monitoring and careful IV fluid management.[4]
Avoid NSAIDs and aspirin in suspected dengue due to bleeding risk. Use acetaminophen for fever and pain.
Disposition Framework
Admit: Confirmed malaria (especially P. falciparum or unknown species), severe dengue, meningitis/encephalitis, hemodynamic instability, inability to tolerate PO, AMS, unknown diagnosis with clinical deterioration.
Discharge with close follow-up: Well-appearing patient with self-limiting viral presentation, negative malaria smears (with plan for repeat), uncomplicated confirmed malaria tolerating PO treatment.
Mandatory reporting: Malaria, dengue, typhoid, cholera, Ebola, and other notifiable diseases must be reported to local/state health department per jurisdictional requirements.
References
- White NJ et al. Malaria. Lancet. 2014;383(9918):723-735. PubMed
- WHO. Guidelines for Malaria. 3rd ed. Geneva: WHO; 2022. WHO
- Bruneel F et al. Severe Imported Falciparum Malaria: A Cohort Study in 400 Critically Ill Adults. PLoS One. 2010;5(10):e13236. PubMed
- WHO. Dengue: Guidelines for Diagnosis, Treatment, Prevention, and Control. 2009. WHO
tydotphrase.com 